Risankizumab: Daily Practice Experience of High Need Patients

Risankizumab: Daily Practice Experience of High Need Patients

Psoriasis is a chronic inflammatory disease which affects 29.5 million people worldwide and it can negatively impact quality of life, especially when it affects a special localization, such as nails, face, palms and soles, or intertriginous regions. Risankizumab is a humanized monoclonal antibody wh...

Full description

Bibliographic Details
Main Authors:	Alexandra M. G. Brunasso, Martina Burlando, Fabrizio Amoruso, Luisa Arancio, Giovanna Malara, Raffaella Manzo, Maria Antonia Montesu, Giacomo Caldarola
Format:	Article
Language:	English
Published:	MDPI AG 2023-06-01
Series:	Biomedicines
Subjects:	psoriasis risankizumab monoclonal antibody
Online Access:	https://www.mdpi.com/2227-9059/11/6/1769

Similar Items

Risankizumab in the treatment of psoriasis – literature review
by: Katarzyna Banaszczyk
Published: (2019-06-01)

Rapidly and successful improvement of nail psoriasis with risankizumab
by: Diego Orsini, et al.
Published: (2023-10-01)

A Case of Erythrodermic Psoriasis Successfully Treated with Risankizumab
by: Megna M, et al.
Published: (2023-12-01)

Risankizumab: an anti-IL-23 antibody for the treatment of psoriasis
by: Haugh IM, et al.
Published: (2018-11-01)

A Case of Recalcitrant Circinate Generalized (Lapière) Psoriasis Successfully Treated with Risankizumab
by: Angelo Ruggiero, et al.
Published: (2022-05-01)

Spotlight on risankizumab and its potential in the treatment of plaque psoriasis: evidence to date
by: Machado Á, et al.
Published: (2018-11-01)

Erythrodermic Psoriasis Managed with Risankizumab
by: Abdulmajeed Alajlan, et al.
Published: (2022-08-01)

Guselkumab, tildrakizumab, and risankizumab in a real-world setting: drug survival and effectiveness in the treatment of psoriasis and psoriatic arthritis
by: Cathrine Dawn Büttner Elgaard, et al.
Published: (2023-12-01)

A severe psoriasis flare after COVID-19 treated with risankizumab: complete skin clearance after 16 weeks
by: Luciano Ibba, et al.
Published: (2023-06-01)

Real-life Effectiveness and Safety of Risankizumab in Moderate-to-severe Plaque Psoriasis: A 40-week Multicentric Retrospective Study
by: Riccardo G. Borroni, et al.
Published: (2021-11-01)

Use of risankizumab in two HIV-positive patients with psoriasis
by: Khalad Maliyar, MD, BA, et al.
Published: (2023-03-01)

Effectiveness of risankizumab in the treatment of palmoplantar psoriasis: a 52-week Italian real-life experience
by: Giacomo Caldarola, et al.
Published: (2023-01-01)

Risankizumab for Plaque and Guttate Psoriasis in a Patient With IgA-Related Glomerulonephritis
by: Annunziata Dattola, et al.
Published: (2021-10-01)

An economic evaluation of risankizumab versus other biologic treatments of moderate to severe plaque psoriasis in Japan
by: Hidehisa Saeki, et al.
Published: (2022-01-01)

New possibilities of systemic therapy of plaque psoriasis with the IL23p19 inhibitor risankizumab
by: O. V. Zhukova, et al.
Published: (2021-06-01)

Effectiveness, Tolerability, and Drug Survival of Risankizumab in a Real-World Setting: A Three-Year Retrospective Multicenter Study—IL PSO (ITALIAN LANDSCAPE PSORIASIS)
by: Luigi Gargiulo, et al.
Published: (2024-01-01)

Risankizumab for the Treatment of the Patients with Moderate to Severe Plaque Psoriasis During a 24-Week Period: Real-Life Experience
by: Gönülal M, et al.
Published: (2023-12-01)

Efficacy, safety, usability, and acceptability of risankizumab 150 mg formulation administered by prefilled syringe or by an autoinjector for moderate to severe plaque psoriasis
by: Andrew Blauvelt, et al.
Published: (2022-05-01)

Risankizumab for the Treatment of Palmoplantar Pustular Psoriasis: A Report of Two Cases
by: Luigi Gargiulo, et al.
Published: (2023-04-01)

Risankizumab for the Treatment of Moderate to Severe Psoriasis: Impact on Health-Related Quality of Life and Psychological Wellbeing
by: Gracia-Cazaña T, et al.
Published: (2023-01-01)

Rapid Response of Palmoplantar Psoriasis to Risankizumab: A Case Report
by: Al Muqrin AM, et al.
Published: (2022-10-01)

Long-Term Efficacy and Safety of Risankizumab for Moderate to Severe Psoriasis: A 2-Year Real-Life Retrospective Study
by: Matteo Megna, et al.
Published: (2023-04-01)

Switching to risankizumab from ustekinumab or adalimumab in plaque psoriasis patients improves PASI and DLQI outcomes for sub-optimal responders
by: Bruce Strober, et al.
Published: (2022-10-01)

Effectiveness of risankizumab in plaque psoriasis with involvement of difficult-to-treat areas: a real-world experience from two referral centers
by: Diego Orsini, et al.
Published: (2023-12-01)

Mycosis fungoides diagnosed after exposure to risankizumab for psoriasis
by: Lauren M. Fahmy, BS, et al.
Published: (2023-11-01)

Efficacy and safety of treatment of moderate and severe psoriasis with the interleukin 23 inhibitor risankizumab
by: Andrey L. Bakulev, et al.
Published: (2022-09-01)

Pharmacovigilance of Risankizumab in the Treatment of Psoriasis and Arthritic Psoriasis: Real-World Data from EudraVigilance Database
by: Fabrizio Calapai, et al.
Published: (2023-07-01)

Cost per responder for risankizumab vs secukinumab in patients with moderate-to-severe plaque psoriasis in Italy
by: Paolo Gisondi, et al.
Published: (2021-09-01)

Impact of PASI response on work productivity and the effect of risankizumab on indirect costs using machine learning in patients with moderate-to-severe psoriasis
by: Mark Lebwohl, et al.
Published: (2022-05-01)

Efficacy and safety of risankizumab for moderate-to-severe plaque psoriasis in clinical practice: A 16-week Canadian retrospective multicenter cohort study
by: Yuliya Lytvyn, PhD, et al.
Published: (2022-03-01)

Successful treatment of psoriasis with risankizumab in a patient with telangiectasia macularis eruptiva perstans
by: Cara Barber, MD, MPH, et al.
Published: (2022-06-01)

Risankizumab: Efficacy, Safety, and Survival in the Mid-Term (52 Weeks) in Real Clinical Practice in Andalusia, Spain, According to the Therapeutic Goals of the Spanish Psoriatic Guidelines
by: Ricardo Ruiz-Villaverde, et al.
Published: (2022-11-01)

New-onset systemic lupus erythematous in a patient receiving risankizumab for psoriasis
by: Cara Barber, MD, MPH, et al.
Published: (2022-07-01)

Efficacy and Safety of Risankizumab in Hidradenitis Suppurativa: A Case Series
by: Federica Repetto, et al.
Published: (2022-09-01)

Risankizumab Therapy for Moderate-to-Severe Psoriasis—A Multi-Center, Long-Term, Real-Life Study from Poland
by: Michał Adamczyk, et al.
Published: (2023-02-01)

Real-world practice indirect comparison between guselkumab, risankizumab, and tildrakizumab: results from an Italian 28-week retrospective study
by: Matteo Megna, et al.
Published: (2022-08-01)

Real-world effectiveness and safety of risankizumab in patients with plaque psoriasis in whom guselkumab failed recently: A multicenter retrospective study of switching within the interleukin-23 inhibitor class
by: Ahmed Bagit, BSc, et al.
Published: (2023-09-01)

Acquired perforating dermatosis associated with risankizumab
by: Munira Alhadlg, MD, et al.
Published: (2024-03-01)

Management of Plaque Psoriasis: A Review and Comparison of IL-23 Inhibitors
by: Nicole L. Bolick, et al.
Published: (2020-12-01)

Guselkumab, Risankizumab, and Tildrakizumab in the Management of Psoriasis: A Review of the Real-World Evidence
by: Ruggiero A, et al.
Published: (2022-08-01)